Charles Powell, MD

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Key opinion leaders share risk-benefit considerations when utilizing therapies that may increase a patient’s risk of developing ILD.

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Charles Powell, MD, MBA, discusses remaining questions with interstitial lung disease in HER2-positive breast cancer.

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.